Overview

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1.
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Cancer Hospital
Treatments:
Apatinib
Oxaliplatin
Tegafur